Turshudzhyan A, Tadros M. Cautious optimism in anticipation of hepatitis B curative therapies.
World J Virol 2022;
11:212-215. [PMID:
36159610 PMCID:
PMC9372785 DOI:
10.5501/wjv.v11.i4.212]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Revised: 05/15/2022] [Accepted: 07/18/2022] [Indexed: 02/06/2023] Open
Abstract
Despite relative effectiveness of current hepatitis B therapies, there is still no curative agents available. The new emerging approaches hold promise to achieve cure and loss of hepatitis B surface antigen. Studies or clinical trials investigating new therapies remain small and either focus on patients with low viral load and without hepatotoxic injury or patients with hepatitis D co-infection, which makes it challenging to assess their effectiveness and side effect profile in hepatitis B population.
Collapse